secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-182137
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports positive Phase 1 data for pan-RAS glue ERAS-0015: 62% uORR in 2L+ KRAS G12X NSCLC
--------------------------------------------------------------------------------

- 62% unconfirmed ORR at 8 weeks in 2L+ KRAS G12X NSCLC at PADs 16-32 mg QD (N=37), exceeding RMC-6236 by 24 ppt.
- 40% unconfirmed ORR at 14 weeks in 2L KRAS G12X PDAC at PADs (N=20), exceeding comparator by 11 ppt.
- 100% of patients (14/14) at PADs showed ≥75% reduction in KRAS G12X ctDNA; 5 showed 100% reduction.
- No DLTs; well-tolerated with no discontinuations due to TRAEs; one Grade 5 pneumonitis event after withdrawal of care.
- Monotherapy RDEs set at 24 and 32 mg QD; expansion and combo dose escalation initiated ahead of guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526182137/0001193125-26-182137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526182137/d126999d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-182137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer